A detailed history of Callan Family Office, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Callan Family Office, LLC holds 1,569 shares of REGN stock, worth $1.04 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
1,569
Holding current value
$1.04 Million
% of portfolio
0.07%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025

BUY
$701.85 - $1046.91 $1.1 Million - $1.64 Million
1,569 New
1,569 $1.12 Billion
Q1 2023

May 12, 2023

BUY
$680.49 - $826.97 $534,865 - $649,998
786 New
786 $646 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $71.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Callan Family Office, LLC Portfolio

Follow Callan Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callan Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callan Family Office, LLC with notifications on news.